Knight Therapeutics Inc. reconfirmed earnings guidance for the year 2024. Knight expects to generate between $335 million to $350 million in revenues.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6 CAD | +3.63% | -.--% | +15.61% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.61% | 446M | |
+15.54% | 78.51B | |
+13.97% | 9B | |
+58.17% | 4.96B | |
-14.94% | 4.84B | |
-.--% | 3.72B | |
-26.63% | 2.19B | |
+16.75% | 2.12B | |
-37.97% | 1.94B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- GUD Stock
- News Knight Therapeutics Inc.
- Knight Therapeutics Inc. Reconfirms Earnings Guidance for the Year 2024